Tirzepatide represents a major advance in the treatment of obesity and type 2 diabetes. As the first dual agonist of GIP and GLP-1 receptors, this molecule developed by Eli Lilly acts simultaneously on two complementary hormonal pathways to produce metabolic effects superior to those of mono-agonists.
What is Tirzepatide?
Tirzepatide is a synthetic 39-amino acid peptide designed to simultaneously activate two hormonal receptors: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. Marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, it received marketing authorization in Europe in 2022.
Unlike simple GLP-1 agonists such as semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda), tirzepatide utilizes a dual mechanism of action. This approach is inspired by a fundamental clinical observation: the two natural incretin hormones, GIP and GLP-1, play complementary yet distinct roles in the regulation of energy metabolism.
The Incretin System: GLP-1 and GIP
Incretins are hormones secreted by the intestine in response to food intake. They account for approximately 50 to 70% of the insulin response after a meal, a phenomenon known as the incretin effect.
GLP-1 (glucagon-like peptide-1) is produced by L cells in the ileum and colon. Its main actions include:
- Stimulation of glucose-dependent insulin secretion
- Inhibition of glucagon secretion (hyperglycemic hormone)
- Slowing of gastric emptying, prolonging the feeling of satiety
- Direct action on appetite centers in the hypothalamus and brainstem
- Neuroprotective and cardioprotective effects demonstrated in preclinical studies
GIP (glucose-dependent insulinotropic polypeptide) is secreted by K cells in the duodenum and jejunum. Long considered less important, its effects are in fact complementary:
- Potent stimulator of insulin secretion, responsible for approximately 60% of the total incretin effect
- Direct action on adipose tissue: promotes lipid storage during periods of abundance, but promotes lipolysis during sustained pharmacological activation
- Role in bone metabolism: stimulation of bone formation via osteoblasts
- Action on the central nervous system: modulation of appetite and food reward
The GIP + GLP-1 Synergy: Tirzepatide’s Dual Agonism
The design of tirzepatide is based on an elegant pharmacological principle: combining the effects of both incretins in a single molecule. The peptide structure is based on the native human GIP sequence, modified to retain significant affinity for the GLP-1 receptor.
Pharmacological data show that tirzepatide exhibits:
| Parameter | GIP-R Affinity | GLP-1R Affinity |
|---|---|---|
| Relative Affinity | Equivalent to native GIP | ~5x lower than native GLP-1 |
| Receptor Activation | Full Agonist | Biased Partial Agonist |
| Estimated Clinical Contribution | ~60 % | ~40 % |
This distribution is not coincidental. Studies by Willard et al. (Science, 2020) demonstrated that tirzepatide’s signaling bias on the GLP-1 receptor — favoring the cAMP pathway over the beta-arrestin pathway — allows for powerful metabolic effects with fewer nausea incidents than pure GLP-1 agonists.
Mechanism of Action on Weight Loss
Tirzepatide acts on weight loss through several converging mechanisms:
1. Appetite Reduction via the Central Nervous System
Both hormones activate distinct neurons in the hypothalamus. GLP-1 primarily acts on the nucleus of the solitary tract (NTS) and the arcuate nucleus, reducing hunger signals. GIP activates complementary pathways in the lateral hypothalamus and prefrontal cortex, modulating food motivation and the reward circuit. The combined effect produces an appetite reduction of 25 to 40%, superior to that observed with GLP-1 alone.
2. Slowing of Gastric Emptying
GLP-1 significantly slows the passage of food from the stomach to the small intestine. This dose-dependent effect prolongs gastric distension and mechanical satiety signals. Tirzepatide maintains this effect, but with partial tolerance developing after 4 to 8 weeks, which explains the gradual decrease in nausea over the course of treatment.
3. Action on Adipose Tissue Metabolism
This is where GIP makes a major difference. GIP receptors are highly expressed in white adipose tissue. Sustained pharmacological activation by tirzepatide induces:
- An increase in lipolysis (mobilization of stored fats)
- An improvement in insulin sensitivity in adipose tissue
- A reduction in visceral adipose tissue inflammation
- Partial browning of white adipose tissue (increase in thermogenesis)
The SURMOUNT-1 study demonstrated that 85.1% of weight loss with tirzepatide 15 mg came from fat mass, significantly preserving lean mass compared to other treatments (Jastreboff et al., NEJM, 2022).
4. Improvement in Glucose Metabolism
Dual agonism potentiates the postprandial insulin response. Tirzepatide restores the first phase of insulin secretion, often impaired in diabetic and pre-diabetic patients. It also reduces hepatic glucose production by inhibiting glucagon secretion.
Pharmacokinetics: Why a Once-Weekly Injection
Native tirzepatide would be degraded within minutes by the DPP-4 enzyme and renal elimination. Three structural modifications give it a half-life of 5 days, allowing for weekly administration:
- C20 fatty acid acylation: A 20-carbon lipid chain is grafted onto the peptide, allowing it to bind to serum albumin. This reversible binding creates a circulating reservoir that gradually releases the active molecule.
- Residue substitution: Non-natural amino acids (such as alpha-aminoisobutyric acid, or Aib) replace certain protease-sensitive residues, making the molecule resistant to enzymatic degradation.
- Peptide spacer: A linker connects the fatty acid to the peptide in an optimal way to maintain biological activity while maximizing albumin binding.
Peak plasma concentration is reached between 8 and 72 hours after subcutaneous injection, with steady-state achieved after 4 weeks of weekly treatment.
Comparison with GLP-1 Mono-Agonists
The following table compares the mechanisms of action of the main molecules in this class:
| Molecule | Targets | Max Weight Loss (%) | HbA1c Reduction | Half-life |
|---|---|---|---|---|
| Tirzepatide (Mounjaro) | GIP + GLP-1 | 22,5 % | -2,07 % | 5 days |
| Semaglutide (Ozempic/Wegovy) | GLP-1 alone | 16,9 % | -1,86 % | 7 days |
| Liraglutide (Saxenda) | GLP-1 alone | 8,0 % | -1,24 % | 13 hours |
| Dulaglutide (Trulicity) | GLP-1 alone | 5,0 % | -1,51 % | 5 days |
Source: meta-analysis by Sattar et al., The Lancet, 2023; SURMOUNT-1, STEP-1, SCALE data.
Tirzepatide’s Target Organs
Tirzepatide exerts its effects on multiple organs:
Brain: Reduction of appetite and modification of food preferences (decreased attraction to fatty and sugary foods). GIP and GLP-1 receptors are co-expressed in the hypothalamus, amygdala, and insular cortex.
Pancreas: Stimulation of insulin secretion by beta cells, in a glucose-dependent manner (very low risk of hypoglycemia in monotherapy). Reduction of glucagon secretion by alpha cells.
Liver: Reduction of hepatic glucose production, decrease in hepatic steatosis (fat accumulation in the liver). The SYNERGY-NASH study showed resolution of NASH in 74% of patients on tirzepatide 15 mg.
Stomach: Slowing of gastric emptying, prolonging postprandial mechanical satiety.
Adipose tissue: Mobilization of lipid reserves, improvement of insulin sensitivity, reduction of inflammation, partial browning promoting thermogenesis.
Cardiovascular system: Beneficial effects on blood pressure, lipid profile (25% reduction in triglycerides, increase in HDL-cholesterol), and reduction of inflammatory markers (CRP, IL-6).
Future Perspectives of Dual Agonism
The success of tirzepatide has paved the way for even more complex molecules:
- Retatrutide (Eli Lilly): Triple GIP/GLP-1/glucagon agonist, with preliminary results showing 24.2% weight loss at 48 weeks (Phase 2 study, Jastreboff et al., NEJM, 2023)
- Survodutide (Boehringer Ingelheim): Dual GLP-1/glucagon agonist, specifically targeting hepatic steatosis
- Orforglipron (Eli Lilly): First oral non-peptide GLP-1 agonist, eliminating the need for injections
- CagriSema (Novo Nordisk): Combination of semaglutide + cagrilintide (amylin analogue), with weight loss results superior to semaglutide alone
Key Takeaways
Tirzepatide represents a paradigm shift in obesity pharmacology. Its dual mechanism of action — simultaneously activating GIP and GLP-1 receptors — produces a metabolic synergy that surpasses mono-agonists in three aspects: weight loss, glycemic control, and cardiometabolic markers. Understanding these mechanisms helps patients and healthcare professionals optimize the use of this molecule.
FAQ
Is tirzepatide a GLP-1 agonist?
Tirzepatide is more than just a GLP-1 agonist. It is a dual agonist that activates both GIP and GLP-1 receptors, distinguishing it from molecules like semaglutide or liraglutide, which only target GLP-1.
Why is dual agonism more effective?
Simultaneous activation of both receptors produces complementary effects: GLP-1 reduces appetite and slows gastric emptying, while GIP improves adipose tissue metabolism and potentiates the insulin response.
Does tirzepatide cause less nausea than semaglutide?
Comparative studies suggest that nausea with tirzepatide is generally less severe and of shorter duration than with semaglutide, thanks to the signaling bias on the GLP-1 receptor.
How long does it take for tirzepatide to reach its full effect?
Plasma steady-state is reached in 4 weeks. The maximum effect on weight loss generally requires 36 to 72 weeks to reach the target dose and allow metabolic adaptations to fully establish.
Is the mechanism of action the same for diabetes and obesity?
Yes, the molecule and its mechanism are identical. Mounjaro is approved for type 2 diabetes, Zepbound for obesity. Same molecule, same doses, different packaging.
Sources
- Willard FS et al. Tirzépatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
- Jastreboff AM et al. Tirzépatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387(3):205-216.
- Sattar N et al. Tirzépatide cardiovascular event risk assessment. The Lancet. 2023.
- Min T, Bain SC. The Rôle of Tirzépatide, Dual GIP and GLP-1 Receptor Agonist. Diabetes Ther. 2021;12(3):1007-1024.
- Nauck MA, Muller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66:1780-1795.
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837.
- HAS. Avis de la Commission de la Transparence – Mounjaro. 2023.